NASDAQ
74.95USD
+4.22 (+5.97%)
We have scored 29 news catalysts on BridgeBio Pharma, Inc. (BBIO) over the past 12 months. The biggest single-day move next to one of them came Nov 23, 2025, when BBIO closed +5.4%: “BridgeBio Pharma: Set For New Commercial Launches After Trial Successes”. Coverage across the window leans positive (average ticker sentiment +0.54). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
14.6B
P/E
—
EPS
—
Beta
0.97
52W range
60.22-93.42
Day range
71.91–75.85
Open
71.98
Prev close
70.73
Volume
5.8M
Avg volume
3.1M
Dividend
0.00
IPO
2019-06-27
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about BridgeBio Pharma, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of BridgeBio Pharma, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for BBIO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
